ZYNE Crosses Above Average Analyst Target
March 16, 2021 at 11:02 AM EDT
In recent trading, shares of Zynerba Pharmaceuticals Inc (ZYNE) have crossed above the average analyst 12-month target price of $6.95, changing hands for $7.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..